Status:
COMPLETED
Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Parkinson Disease
Eligibility:
All Genders
Brief Summary
Assessment of daily maintenance dose of Sifrol®, L-dopa sparing effect, effect on tremor, depression, anhedonia and tolerability
Eligibility Criteria
Inclusion
- Patients with advanced idiopathic Parkinson's disease for whom combined treatment with Sifrol and L-dopa was indicated
Exclusion
- NA
Key Trial Info
Start Date :
October 1 1998
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
657 Patients enrolled
Trial Details
Trial ID
NCT02248220
Start Date
October 1 1998
Last Update
September 25 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.